(Reuters) – Institutional investors doubt that treatments for Alzheimer’s disease being developed by Pfizer Inc and Eli Lilly will achieve the main goals of their ongoing late-stage trials, but hopes are running far higher for the Pfizer drug, according to a survey by ISI Group Inc.
Recent Posts
Categories